Replies to post #69942 on Biotech Values

[ariadndndough]

thanks for replying

[DewDiligence]

MK-7009 Phase-1b Results

[These charts have a little more detail than
what MRK presented on its Dec 9 R&D webcast.
The data look very good indeed, and MK-7009
could be a serious player in the HCV PI arena.
Unfortunately for investors, we probably won’t
get any data from the phase-2a trial until AASLD
2009 or MRK’s next R&D Day in Dec 2009.]


Efficacy data:



Safety data
(AE’s with >=2 cases in all cohorts combined):


Source: http://www.natap.org/2008/AASLD/AASLD_09.htm